Vivani Medical, Inc. - Common Stock VANI 深 滬
等待開盤 08-23 09:30:00 美东时间
1.24
+0.030
+2.48%
華盛通- 最 高1.2516
- 今 開1.21
- 成交量 3.25万股
- 最 低 1.2001
- 昨 收 1.21
- 總市值 7346.24万
- 52周最高 1.80
- 市盈率 靜 --
- 換手率 0.05%
- 52周最低 0.9054
- 委 比 -38.75%
- 總股本 5924.39万
- 歷史最高 576.48
- 量 比 0.65
- 振 幅 4.26%
- 歷史最低 0.7536
- 每 手 1
- 風險率 0.13%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Vivani Medical CEO Adam Mendelsohn to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025
Vivani Medical, Inc. announced that CEO Adam Mendelsohn will present and host partnering meetings at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025, in New York. Mendelsohn will discuss Vivani's miniature, ultra-long-acting drug implants, including the advancement of NPM-139, a semaglutide implant for chronic weight management. The presentation will highlight the Company's NanoPortal™ technology, aimed at impro...
08-20 12:30
Vivani Medical Secures $10M Through Share Purchase Agreement
Vivani Medical ( ($VANI) ) has shared an update. On August 11, 2025, Vivani Med...
08-14 05:17
Vivani Medical Q2 EPS $(0.12) Misses $(0.10) Estimate
Vivani Medical (NASDAQ:VANI) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.10) by 20 percent. This is a 20 percent decrease over losses of $(0.10) per share from the
08-14 04:22
EXCLUSIVE: Vivani Prioritizes Semaglutide-Based Implant After Promising Preclinical Data
Vivani reported Phase 1 success for its exenatide implant and shared preclinical semaglutide data showing 231-day weight loss from a single dose.
08-05 19:32
Vivani Medical Announces Rapid Advancement of NPM-139, a Novel Semaglutide Implant, Following Positive Weight Loss Data from an Ongoing Preclinical Study of NPM-139 and Promising Results from the LIBERATE-1 Phase 1 Clinical Study of NPM-115
Vivani Medical reported positive results from the LIBERATE-1 Phase 1 study of NPM-115, the first-in-human application of its NanoPortal implant technology, demonstrating safety, tolerability, and meeting primary objectives. New preclinical data for NPM-139, a semaglutide implant, showed sustained weight loss of approximately 20% over 6 months, supporting its potential for annual dosing. Based on these results, Vivani prioritizes advancing NPM-139...
08-05 12:10
Elizabeth Warren On Democrats' Support Of Crypto Bills: 'Long, Bipartisan Tradition Of Helping Out Industry' Instead Of Working For Average American
Sen. Elizabeth Warren (D-Mass.) voiced her dissatisfaction with recent endorsements of cryptocurrency bills by Democratic lawmakers.
07-25 18:31
Vivani Medical Updates on Exenatide Implant Progress
Vivani Medical ( ($VANI) ) has issued an announcement. Vivani Medical has relea...
06-17 18:47
Vivani Medical appoints Anthony Baldor as CFO
Vivani Medical (NASDAQ:VANI) announced on Wednesday the appointment of Anthony Baldor as chief financial officer (CFO). Baldor succeeds Brigid A. Makes, who has decided to retire from Vivani to focus ...
06-11 20:08
Vivani Medical Appoints Anthony Baldor as Chief Financial Officer
Vivani Medical, Inc. appoints Anthony Baldor as Chief Financial Officer, succeeding Brigid A. Makes who is retiring. Baldor, with over 20 years of experience in biotechnology finance, joins from Diakonos Oncology Corp. and 4D Molecular Therapeutics, Inc. The company, focused on developing ultra-long-acting drug implants, commends Makes for her contributions during transformative growth. Vivani's pipeline includes products for chronic weight manag...
06-11 12:00
Vivani Medical to Present at the 2025 BIO International Convention
Vivani Medical, Inc. CEO Adam Mendelsohn will present the company's miniature, ultra long-acting drug implants at the 2025 BIO International Convention in Boston. The implants, powered by the proprietary NanoPortal™ technology, aim to improve medication adherence in chronic disease management. Vivani's lead programs, NPM-115 and NPM-139, are GLP-1 implants under development for chronic weight management. Results from the LIBERATE-1 trial for NPM-...
06-10 12:30
